Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial-Reference-Cited by-同舟云学术

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Published:2007-06 Issue:9580 Volume:369 Page:2161-2170
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Paavonen Jorma,Jenkins David,Bosch F Xavier,Naud Paulo,Salmerón Jorge,Wheeler Cosette M,Chow Song-Nan,Apter Dan L,Kitchener Henry C,Castellsague Xavier,de Carvalho Newton S,Skinner S Rachel,Harper Diane M,Hedrick James A,Jaisamrarn Unnop,Limson Genara AM,Dionne Marc,Quint Wim,Spiessens Bart,Peeters Pascal,Struyf Frank,Wieting Susan L,Lehtinen Matti O,Dubin Gary

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide;Walboomers;J Pathol,1999

2. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer;Stanley;Br J Cancer,2007

3. The epidemiology of genital human papillomavirus infection;Trottier;Vaccine,2006

4. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update;Smith;Int J Cancer,2007

5. Epidemiologic classification of human papillomavirus types associated with cervical cancer;Muñoz;N Engl J Med,2003

Cited by 1076 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59;Vaccine;2024-10

2. Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study;npj Vaccines;2024-08-13

3. Validation of a triple‐color pseudovirion‐based neutralization assay for immunogenicity assessment of a 14‐valent recombinant human papillomavirus vaccine;Journal of Medical Virology;2024-08

4. IDENTIFYING PLAUSIBLE RANGES FOR DIFFERENTIAL VACCINE EFFICACY ACROSS HIGH- AND LOW-INCOME SETTINGS: A SYSTEMATIC REVIEW, DESCRIPTIVE META-ANALYSIS, AND ILLUSTRATIVE EVIDENCE ANALYSIS;2024-08-01

5. Human Papillomavirus (HPV) Infection and Risk Behavior in Vaccinated and Non-Vaccinated Paraguayan Young Women;Pathogens;2024-02-27